These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 20168286)

  • 1. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
    Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
    Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung.
    Traub T; Petkov V; Ofluoglu S; Pangerl T; Raderer M; Fueger BJ; Schima W; Kurtaran A; Dudczak R; Virgolini I
    J Nucl Med; 2001 Sep; 42(9):1309-15. PubMed ID: 11535718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
    Rodrigues M; Traub-Weidinger T; Leimer M; Li S; Andreae F; Angelberger P; Dudczak R; Virgolini I
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Biological Evaluation of
    Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
    Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
    Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
    J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.
    Gabriel M; Andergassen U; Putzer D; Kroiss A; Waitz D; Von Guggenberg E; Kendler D; Virgolini IJ
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):92-9. PubMed ID: 20168291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.
    Li S; Kurtaran A; Li M; Traub-Weidinger T; Kienast O; Schima W; Angelberger P; Virgolini I; Raderer M; Dudczak R
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1087-95. PubMed ID: 12768334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of
    Zhu W; Cheng Y; Jia R; Zhao H; Bai C; Xu J; Yao S; Huo L
    J Nucl Med; 2021 Oct; 62(10):1398-1405. PubMed ID: 33579804
    [No Abstract]   [Full Text] [Related]  

  • 13. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
    Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
    J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
    Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
    [No Abstract]   [Full Text] [Related]  

  • 15. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.
    Ocak M; Demirci E; Kabasakal L; Aygun A; Tutar RO; Araman A; Kanmaz B
    Nucl Med Commun; 2013 Nov; 34(11):1084-9. PubMed ID: 23939265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
    Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
    Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.
    Virgolini I; Patri P; Novotny C; Traub T; Leimer M; Füger B; Li SR; Angelberger P; Raderer M; Wogritsch S; Kurtaran A; Kletter K; Dudczak R
    Ann Oncol; 2001; 12 Suppl 2():S41-5. PubMed ID: 11762351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data.
    Middendorp M; Selkinski I; Happel C; Kranert WT; Grünwald F
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):76-83. PubMed ID: 20168289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
    Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
    Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.